Abstract
CRISP is a non-interventional, prospective, multi-center clinical research platform whose aim is to understand the treatment reality of patients (pts) with lung carcinoma in Germany. Here we present first data of pts diagnosed with NSCLC in stages II or III (IIIB/C if treated with curative intent).
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have